Combining MR blockers with ROCK inhibitors may have additive vasoprotective effects that might reduce cardiovascular complications in diabetes as reported by a clinical study demonstrating that eplerenone decreased the enhanced ROCK activity in circulating leukocytes in hypertensive patients41. Here, NR3C2 is linked to diabetes mellitus.